LONDON, July 4, 2026, 22:02 BST
- Tate & Lyle finished Friday at 559p. With the 13.2p final dividend trading ex-dividend, the forward deal value for a new buyer is closer to 601.8p instead of the 615p headline.
- Tate & Lyle and Ingredion sent out the scheme document July 3. Shareholders will meet July 28, and the companies expect to wrap up the process in the second half of 2027.
- A new report says advisory and financing fees could total as much as £163 million, almost 6% of the £2.8 billion equity value.
Tate & Lyle PLC (LON:TATE) is set to return to trading next week, but traders will be watching it as a takeover play instead of a regular food-ingredients name. Shares finished Friday at 559p, leaving them 36p back from Ingredion Incorporated’s NYSE:INGR 595p all-cash offer, and 42.8p under the value an acquirer would get after the final dividend went ex-div.
Arb funds are looking at a cleaner number of about 601.8p here: 595p cash, plus an interim dividend up to 6.8p if paid. The 13.2p final dividend comes July 31, but holders needed to be on the register by the June 19 record date, following the ex-div on June 18.
| Deal math as of Friday’s close | Pence a share | Gross spread to 559p |
|---|---|---|
| Friday close | 559.0 | — |
| Cash bid | 595.0 | 36.0p / 6.4% |
| Cash plus allowed interim dividend | 601.8 | 42.8p / 7.7% |
| Headline value, eligible for final dividend | 615.0 | 56.0p / 10.0% |
The shares gained 3p, or 0.54%, Friday. The stock is up 0.9% since closing at 554p on June 26. The FTSE 250 finished Friday at 23,538.80, up 0.52% for the session. Reuters said London’s main indexes finished higher for the week.
| Last week’s market read | Level or price | Move |
|---|---|---|
| Tate & Lyle closed June 26 at 554p, up to 559p by July 3 | 554p to 559p | +0.9% |
| Tate & Lyle finished Friday at 559p | 559p | +0.54% |
| FTSE 250 ended Friday at 23,538.80 | 23,538.80 | +0.52% |
The latest move wasn’t from trading but came after hours. Tate & Lyle and Ingredion said July 3 that they have sent or made the scheme document available to shareholders. The Court Meeting is set for 11:00 a.m. on July 28, with the General Meeting at 11:15 a.m. at 5 Marble Arch, London. The companies expect to complete the process in the second half of 2027, pending shareholder and court sign-off and antitrust approvals.
Tate’s board called the deal cash certainty following a tough year. The offer said 2026 financial year numbers were “disappointing” and flagged risk on when future value might show up. The board’s advisers, Goldman Sachs and Greenhill, said the terms are fair and reasonable. Investegate
Tate Chair David Hearn said shareholders got a way to “crystallise value in cash” with the offer. Ingredion Chairman and CEO Jim Zallie said the deal would add “expertise and geographic reach”. Investegate
Industry watchers backed the move. Bryan Quoc Le, CEO at Mendocino Food Consulting, told Ingredients Network the deal “absolutely makes sense.” Edible Brands president Matthew Walls said Tate gets scale just as ingredients suppliers face more “complexity.” Ingredients Network
The fee bill adds another layer to the spread. The Times said on Friday that advisers, lawyers, PRs, and finance providers could land up to £163 million, with Tate & Lyle’s side accounting for up to £64.2 million and Ingredion’s for as much as $132.3 million. J.P. Morgan is backing the deal with a $4.225 billion bridge, and the offer announcement said the bank was satisfied Ingredion had enough cash to fund the offer.
Tate & Lyle has the DRIP mandate deadline set for July 10 this week. Next up is proxy voting before meetings planned for July 28.
